Avalo Therapeutics Inc
AVTX18.855USD
-0.315-1.64%
Market hours （ET）Quotes delayed by 15 min
336.14MMarket Cap
LossP/E TTM
More Details of Avalo Therapeutics Inc Company
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Avalo Therapeutics Inc Info
Ticker SymbolAVTX
Company nameAvalo Therapeutics Inc
IPO dateNov 13, 2015
CEONeil (Garry A)
Number of employees23
Security typeOrdinary Share
Fiscal year-endNov 13
Address1500 Liberty Ridge Drive
CityWAYNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone14105228707
Websitehttps://www.avalotx.com/
Ticker SymbolAVTX
IPO dateNov 13, 2015
CEONeil (Garry A)
Company Executives of Avalo Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mitchell Chan
Mr. Mitchell Chan
Independent Director
Independent Director
3.17K
--
Ms. Samantha (Sam) Truex
Ms. Samantha (Sam) Truex
Independent Director
Independent Director
3.17K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
3.17K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
3.17K
--
Ms. Jennifer Riley
Ms. Jennifer Riley
Chief Strategy Officer
Chief Strategy Officer
--
--
Dr. Jonathan Howard Goldman, M.D.
Dr. Jonathan Howard Goldman, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Sullivan, CPA
Mr. Christopher (Chris) Sullivan, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Garry A. Neil, M.D.
Dr. Garry A. Neil, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Mittie Doyle, M.D.
Dr. Mittie Doyle, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Paul C. Varki, J.D.
Mr. Paul C. Varki, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mitchell Chan
Mr. Mitchell Chan
Independent Director
Independent Director
3.17K
--
Ms. Samantha (Sam) Truex
Ms. Samantha (Sam) Truex
Independent Director
Independent Director
3.17K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
3.17K
--
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
3.17K
--
Ms. Jennifer Riley
Ms. Jennifer Riley
Chief Strategy Officer
Chief Strategy Officer
--
--
Dr. Jonathan Howard Goldman, M.D.
Dr. Jonathan Howard Goldman, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
7.47%
OrbiMed Advisors, LLC
7.44%
Nantahala Capital Management, LLC
6.81%
Point72 Asset Management, L.P.
5.81%
Affinity Asset Advisors LLC
5.55%
Other
66.91%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
7.47%
OrbiMed Advisors, LLC
7.44%
Nantahala Capital Management, LLC
6.81%
Point72 Asset Management, L.P.
5.81%
Affinity Asset Advisors LLC
5.55%
Other
66.91%
Shareholder Types
Shareholders
Proportion
Hedge Fund
52.81%
Investment Advisor
10.37%
Private Equity
8.76%
Investment Advisor/Hedge Fund
7.46%
Venture Capital
3.73%
Individual Investor
3.48%
Research Firm
3.41%
Corporation
0.32%
Other
9.66%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
92
15.54M
49.88%
+220.47K
2025Q3
100
15.32M
50.75%
+6.89M
2025Q2
75
7.84M
82.00%
-412.02K
2025Q1
82
8.26M
75.30%
+101.94K
2024Q4
82
7.57M
64.56%
+817.70K
2024Q3
76
6.75M
29.89%
+3.87M
2024Q2
97
946.19K
12.26%
+816.58K
2024Q1
119
129.62K
6.10%
+66.52K
2023Q4
128
65.08K
5.28%
+59.48K
2023Q3
136
5.61K
6.84%
-4.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
1.03M
7.82%
-8.63K
-0.83%
Jun 30, 2025
OrbiMed Advisors, LLC
967.00K
7.35%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
995.00K
7.57%
+95.00K
+10.56%
Jun 30, 2025
Point72 Asset Management, L.P.
588.63K
4.48%
+588.63K
--
Aug 04, 2025
Affinity Asset Advisors LLC
607.87K
4.62%
-49.28K
-7.50%
Jun 30, 2025
The Vanguard Group, Inc.
166.94K
1.27%
--
--
Jun 30, 2025
RA Capital Management, LP
932.97K
7.09%
-34.03K
-3.52%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Health Innovation Active ETF
0.07%
iShares Micro-Cap ETF
0.03%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Health Innovation Active ETF
Proportion0.07%
iShares Micro-Cap ETF
Proportion0.03%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Jul 07, 2022
Merger
12→1
Jul 07, 2022
Merger
12→1
Date
Type
Ratio
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Dec 07, 2023
Merger
240→1
Jul 07, 2022
Merger
12→1
Jul 07, 2022
Merger
12→1
Jul 07, 2022
Merger
12→1
Jul 07, 2022
Merger
12→1
FAQs
Who are the top five shareholders of Avalo Therapeutics Inc?
The top five shareholders of Avalo Therapeutics Inc are:
BVF Partners L.P. holds 1.03M shares, accounting for 7.82% of the total shares.
OrbiMed Advisors, LLC holds 967.00K shares, accounting for 7.35% of the total shares.
Nantahala Capital Management, LLC holds 995.00K shares, accounting for 7.57% of the total shares.
Point72 Asset Management, L.P. holds 588.63K shares, accounting for 4.48% of the total shares.
Affinity Asset Advisors LLC holds 607.87K shares, accounting for 4.62% of the total shares.
BVF Partners L.P. holds 1.03M shares, accounting for 7.82% of the total shares.
OrbiMed Advisors, LLC holds 967.00K shares, accounting for 7.35% of the total shares.
Nantahala Capital Management, LLC holds 995.00K shares, accounting for 7.57% of the total shares.
Point72 Asset Management, L.P. holds 588.63K shares, accounting for 4.48% of the total shares.
Affinity Asset Advisors LLC holds 607.87K shares, accounting for 4.62% of the total shares.
What are the top three shareholder types of Avalo Therapeutics Inc?
The top three shareholder types of Avalo Therapeutics Inc are:
BVF Partners L.P.
OrbiMed Advisors, LLC
Nantahala Capital Management, LLC
BVF Partners L.P.
OrbiMed Advisors, LLC
Nantahala Capital Management, LLC
How many institutions hold shares of Avalo Therapeutics Inc (AVTX)?
As of 2025Q4, 92 institutions hold shares of Avalo Therapeutics Inc, with a combined market value of approximately 15.54M, accounting for 49.88% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.87%.
What is the biggest source of revenue for Avalo Therapeutics Inc?
In --, the -- business generated the highest revenue for Avalo Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
